Showing results (81-90 of 133) with videos related to
Sort By:
Pageof 14
BMC Research Notes|May 25, 2016
Short-term change of carotid intima-media thickness after treatment of hyperglycemia in patients with diabetes: a cross-sectional studyAyumi Tenjin, Yoshio Nagai, Sayaka Yuji, et al.Frontiers in Immunology|February 15, 2021
Inactivation of the PD-1-Dependent Immunoregulation in Mice Exacerbates Contact Hypersensitivity Resembling Immune-Related Adverse EventsMatin Dokht Ashoori, Kensuke Suzuki, Yosuke Tokumaru, et al.Autism Research and Treatment|August 31, 2012
Prenatal and Postnatal Epigenetic Programming: Implications for GI, Immune, and Neuronal Function in AutismMostafa I Waly, Mady Hornig, Malav Trivedi, et al.Plos One|November 21, 2017
Hypoxia and hypoxia-inducible factor (HIF) downregulate antigen-presenting MHC class I molecules limiting tumor cell recognition by T cellsShalini Sethumadhavan, Murillo Silva, Phaethon Philbrook, et al.Journal of Diabetes Investigation|May 21, 2014
Comparison of daily glucose excursion by continuous glucose monitoring between type 2 diabetic patients receiving biphasic insulin aspart 30 or biphasic human insulin 30Akio Ohta, Tomoko Suwa, Yoshiyuki Sada, et al.Endocrine Journal|September 19, 2014
Effect of sitagliptin on glycemic control and beta cell function in Japanese patients given basal-supported oral therapy for type 2 diabetesShiko Asai, Akio Ohta, Hiroyuki Kato, et al.Expert Opinion on Pharmacotherapy|August 4, 2017
Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetesAkio Ohta, Hiroyuki Kato, Satoshi Ishii, et al.Journal of Oleo Science|July 18, 2018
Aggregation Behavior and Thiol-Thioester Exchange for Cationic Surfactants with Propylthioacetate Side ChainTsuyoshi Asakawa, Nao Arai, Akina Fujii, et al.Endocrine Journal|March 24, 2007
Asymmetric dimethylarginine (ADMA) in the aqueous humor of diabetic patientsMotohiko Sugai, Akio Ohta, Yuji Ogata, et al.Expert Opinion on Pharmacotherapy|October 20, 2015
Better response to the SGLT2 inhibitor dapagliflozin in young adults with type 2 diabetesYuta Nakamura, Yoshio Nagai, Yuko Terashima, et al.Pageof 14